Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

lenalidomide krka (previously lenalidomide krka d.d. novo mesto)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

MONTELUKAST/KRKA 4MG/TAB ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

montelukast/krka 4mg/tab μασωμενο δισκιο

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ - 4mg/tab - ineof01106 montelukast sodium 4.160000 mg - montelukast

MONTELUKAST/KRKA 5MG/TAB ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

montelukast/krka 5mg/tab μασωμενο δισκιο

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ - 5mg/tab - ineof01106 montelukast sodium 5.200000 mg - montelukast

MONTELUKAST/KRKA 10MG/TAB ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

montelukast/krka 10mg/tab επικαλυμμενο με λεπτο υμενιο δισκιο

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 10mg/tab - ineof01106 montelukast sodium 10.400000 mg - montelukast

CANDESARTAN+HCTZ/KRKA TAB (8+12,5)MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

candesartan+hctz/krka tab (8+12,5)mg/tab

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - candesartan cilexetil; hydrochlorothiazide - tab (ΔΙΣΚΙΟ) - (8+12,5)mg/tab - candesartan cilexetil 8mg; hydrochlorothiazide 12,5mg - candesartan and diuretics

CANDESARTAN+HCTZ/KRKA TAB (16+12,5)MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

candesartan+hctz/krka tab (16+12,5)mg/tab

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - candesartan cilexetil; hydrochlorothiazide - tab (ΔΙΣΚΙΟ) - (16+12,5)mg/tab - candesartan cilexetil 16mg; hydrochlorothiazide 12,5mg - candesartan and diuretics

CANDESARTAN+HCTZ/KRKA TAB (32+12,5)MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

candesartan+hctz/krka tab (32+12,5)mg/tab

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - candesartan cilexetil; hydrochlorothiazide - tab (ΔΙΣΚΙΟ) - (32+12,5)mg/tab - candesartan cilexetil 32mg; hydrochlorothiazide 12,5mg - candesartan and diuretics

CANDESARTAN+HCTZ/KRKA TAB (32+25)MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

candesartan+hctz/krka tab (32+25)mg/tab

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - candesartan cilexetil; hydrochlorothiazide - tab (ΔΙΣΚΙΟ) - (32+25)mg/tab - candesartan cilexetil 32mg; hydrochlorothiazide 25mg - candesartan and diuretics

ATORVASTATIN/KRKA 10MG/TAB ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

atorvastatin/krka 10mg/tab επικαλυμμενο με λεπτο υμενιο δισκιο

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - atorvastatin calcium trihydrate - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 10mg/tab - ineof01062 atorvastatin calcium trihydrate 10.360000 mg - atorvastatin